Cargando…

Modest deviations from optimal adherence to antiretroviral therapy promote residual HIV-1 replication in the absence of virological rebound in plasma

Detalles Bibliográficos
Autores principales:	Pasternak, Alexander O, de Bruin, Marijun, Jurriaans, Suzanne, Bakker, Margreet, Berkhout, Ben, Prins, Jan M, Lukashov, Vladimir V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236881/ http://dx.doi.org/10.1186/1742-4690-8-S2-O35

Ejemplares similares

Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome
por: Pasternak, Alexander O., et al.
Publicado: (2009)

High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy
por: Pasternak, Alexander O., et al.
Publicado: (2015)

Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution in vivo
por: Pasternak, Alexander, et al.
Publicado: (2013)

Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013
por: van der Kuyl, Antoinette C, et al.
Publicado: (2013)

Has the Rate of CD4 Cell Count Decline before Initiation of Antiretroviral Therapy Changed over the Course of the Dutch HIV Epidemic among MSM?
por: Gras, Luuk, et al.
Publicado: (2013)

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load
por: Cornelissen, Marion, et al.
Publicado: (2006)

Low-level residual viremia and risk of virological failure
por: Cologni, G, et al.
Publicado: (2010)

Antiretroviral therapy adherence monitoring and its impact on immuno-virological outcome
por: Lobodan, Alina, et al.
Publicado: (2014)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
por: Zacharopoulou, P., et al.
Publicado: (2022)

Factors affecting the timing of adiposity rebound
por: Koyama, Satomi, et al.
Publicado: (2013)

Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy
por: Pasternak, Alexander O, et al.
Publicado: (2021)

Cell-associated HIV RNA: a dynamic biomarker of viral persistence
por: Pasternak, Alexander O, et al.
Publicado: (2013)

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients
por: Cooper, C, et al.
Publicado: (2015)

Viral Load Levels Measured at Set-Point Have Risen Over the Last Decade of the HIV Epidemic in the Netherlands
por: Gras, Luuk, et al.
Publicado: (2009)

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
por: Rock, Alex E., et al.
Publicado: (2020)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

CD32(+)CD4(+) T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency
por: Darcis, Gilles, et al.
Publicado: (2020)

HIV-1 dual infection is associated with faster CD4+T cell decline in a cohort of men with primary HIV infection
por: Cornelissen, Marion, et al.
Publicado: (2011)

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users
por: van den Berg, Charlotte H. S. B., et al.
Publicado: (2007)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
por: Mellberg, Tomas, et al.
Publicado: (2011)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy
por: Scherpenisse, Mirte, et al.
Publicado: (2021)

Correlation of lateral deviation and rotation of the spine in static and dynamic surface topography
por: Diers, Helmut, et al.
Publicado: (2014)

HIV replication and evolution in patients on highly active antiretroviral therapy
por: Siliciano, Robert F
Publicado: (2006)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
por: van Paassen, Pien M., et al.
Publicado: (2023)

Lack of Detection of XMRV in Seminal Plasma from HIV-1 Infected Men in The Netherlands
por: Cornelissen, Marion, et al.
Publicado: (2010)

Absence vs. presence
por: Ramkumar, Swaminathane
Publicado: (2014)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
por: Chereau, Fanny, et al.
Publicado: (2017)

Correlation between hump dimensions and side deviation in idiopathic scoliosis before and after a conservative treatment
por: Aulisa, AG, et al.
Publicado: (2009)

Low level viraemia and the risk of virological failure in HIV infected patients
por: Florea, Dragoş, et al.
Publicado: (2014)

Treatment of chronic HBV hepatitis – between immune control and virological control
por: Popescu, Cristina, et al.
Publicado: (2014)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy
por: Gianella, Sara, et al.
Publicado: (2016)

High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011
por: van der Kuyl, Antoinette C, et al.
Publicado: (2013)

Screening for new antiretroviral targets
por: Fassati, Ariberto
Publicado: (2013)

Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway
por: van Montfort, Thijs, et al.
Publicado: (2019)

Occult replication of a conditionally-live attenuated SIV profoundly upregulates T effector memory cell frequency
por: Manoussaka, Maria, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1ki4iprc6rc7b4ob3u3npa88s2